- Home
- AKBA vs ATLC Comparison
AKBA vs ATLC Comparison
Compare AKBA & ATLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- ATLC
- Stock Information
- Founded
- AKBA 2007
- ATLC 1996
- Country
- AKBA United States
- ATLC United States
- Employees
- AKBA N/A
- ATLC N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- ATLC Finance: Consumer Services
- Sector
- AKBA Health Care
- ATLC Finance
- Exchange
- AKBA Nasdaq
- ATLC Nasdaq
- Market Cap
- AKBA 861.7M
- ATLC 900.3M
- IPO Year
- AKBA 2014
- ATLC 1999
- Fundamental
- Price
- AKBA $2.85
- ATLC $72.26
- Analyst Decision
- AKBA Strong Buy
- ATLC Buy
- Analyst Count
- AKBA 5
- ATLC 7
- Target Price
- AKBA $6.90
- ATLC $76.29
- AVG Volume (30 Days)
- AKBA 3.6M
- ATLC 45.7K
- Earning Date
- AKBA 11-06-2025
- ATLC 11-06-2025
- Dividend Yield
- AKBA N/A
- ATLC N/A
- EPS Growth
- AKBA N/A
- ATLC 35.13
- EPS
- AKBA N/A
- ATLC 5.69
- Revenue
- AKBA $203,733,000.00
- ATLC $457,158,000.00
- Revenue This Year
- AKBA $43.91
- ATLC $293.56
- Revenue Next Year
- AKBA $32.09
- ATLC $12.64
- P/E Ratio
- AKBA N/A
- ATLC $12.77
- Revenue Growth
- AKBA 16.75
- ATLC 26.20
- 52 Week Low
- AKBA $1.24
- ATLC $31.10
- 52 Week High
- AKBA $4.08
- ATLC $78.91
- Technical
- Relative Strength Index (RSI)
- AKBA 38.07
- ATLC 66.16
- Support Level
- AKBA $2.91
- ATLC $71.77
- Resistance Level
- AKBA $3.02
- ATLC $78.91
- Average True Range (ATR)
- AKBA 0.13
- ATLC 2.66
- MACD
- AKBA -0.00
- ATLC 0.07
- Stochastic Oscillator
- AKBA 11.90
- ATLC 53.04
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.